Keenova Therapeutics plc
11.90%
4,702,714
1567892
G5890A102
Dec 7, 2025
Dec 10, 2025, 06:29 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Silver Point Capital, L.P. | Investment Adviser | 11.90% | 4,702,714 | 0 | 4,702,714 |
| Edward A. Mule | Individual | 11.90% | 4,702,714 | 0 | 4,702,714 |
| Robert J. O'Shea | Individual | 11.90% | 4,702,714 | 0 | 4,702,714 |
Disclosure Items (4)
Common Stock, par value $0.01 per share
Keenova Therapeutics plc
College Business & Technology Park, Dublin 15, L2, D15 TX2V
Item 3 of the Schedule 13D is hereby supplemented as follows: The source of funds used in the acquisitions reported in Item 5 was working capital of the Reporting Persons.
The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference. The Reporting Persons currently beneficially own 4,702,714 shares of Common Stock, representing 11.9% of the shares of Common Stock outstanding. As reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2025, as of November 7, 2025, there were 39,526,162 shares of Common Stock issued and outstanding.
The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Amendment are incorporated herein by reference.
The following sets forth all transactions in the Common Stock effected by the Reporting Persons since the Reporting Persons' most recent filing on Schedule 13D with respect to the Common Stock: On December 8, 2025, the Reporting Persons purchased 130,974 shares of Common Stock at a price per share of $88.75 in the open market through brokers. On November 19, 2025, the Reporting Persons purchased 42,000 shares of Common Stock at a price per share of $88.875 in the open market through brokers. On November 17, 2025, the Reporting Persons purchased 26,000 shares of Common Stock at a price per share of $88.875 in the open market through brokers. On November 10, 2025, the Reporting Persons purchased 290,000 shares of Common Stock at a price per share of $93.75 in the open market through brokers.
Other than as disclosed in Item 4, no person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock held by the Reporting Persons.
Not applicable.
Exhibit No. Description 1 Joint Filing Agreement, dated as of December 10, 2025, by and among the Reporting Persons 2 Power of Attorney of Robert J. O'Shea and Edward A. Mule (incorporated here by reference to Schedule 13G filed by Silver Point Capital, L.P., Edward A. Mule and Robert J. O'Shea with the Securities and Exchange Commission on February 16, 2016 relating to TopBuild Corp.)